<DOC>
	<DOCNO>NCT02464137</DOCNO>
	<brief_summary>single-modality phase I dose escalation toxicity study first-line curative treatment head neck squamous cell carcinoma .</brief_summary>
	<brief_title>HYpofractionateD RadioAblative ( HYDRA ) Treatment Advanced Laryngeal Cancer</brief_title>
	<detailed_description>HYDRA consist 5 fraction SBRT treatment target grossly evident disease localize examination standard diagnostic CT , MR , PET-CT imaging . Prophylactic coverage uninvolved at-risk mucosal nodal drainage basin strictly disallow . The initial dose cohort treat total 42.5 Gy five equal fraction deliver every day two week period ( biologically equivalent 66 Gy deliver 2 Gy daily fraction ) , draw successful institutional experience similar dose fractionation early-stage larynx SBRT . Escalation total dose proceed 2.5 Gy increment , final target dose 50 Gy .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<criteria>Patients older 18 year age histologically proven squamous cell carcinoma larynx . Stage T12N12c/T34N02c disease , define American Joint Committee Cancer ( AJCC ) criterion . ECOG ( Zubrod ) performance status 02 . Must functionally technically fit partial laryngectomy . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 90 day follow completion therapy . Ability understand willingness sign write informed consent Patients undergone resection primary disease . Patients receive induction chemotherapy cancer diagnosis . Patients undergone divert tracheostomy either ) traverse directly tumor , b ) place true airway insufficiency . Patients tracheostomy place preemptively impend airway compromise remain eligible enrollment . Prior cancer diagnosis , except appropriately treat localized epithelial skin cancer cervical cancer . Prior radiation therapy head neck region . Women childbearing potential ( woman childbearing potential reproductively mature woman undergone hysterectomy naturally postmenopausal least 24 consecutive month [ i.e. , menses time precede 24 consecutive month ] ) male participant must practice effective contraception ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study . Patients unable unwilling give write , informed consent . Severe , active comorbidity , define follow : 1 . Unstable angina and/or congestive heart failure require hospitalization within last 6 month . 2 . Transmural myocardial infarction within last 6 month . 3 . Acute bacterial fungal infection require intravenous antibiotic time registration . 4 . Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy within 30 day registration . 5 . Hepatic insufficiency result clinical jaundice and/or coagulation defect ; note , however , laboratory test liver function coagulation parameter require entry protocol . 6 . Acquired Immune Deficiency Syndrome ( AIDS ) base upon current CDC definition ; note , however , HIV test require entry protocol . Protocolspecific requirement may also exclude immunocompromised patient . 7 . History treatment potent immunosuppressive drug condition post organ transplant , severe rheumatoid arthritis , etc . within past 6 month . Subjects must pregnant nursing due potential congenital abnormality potential regimen harm nursing infant Evidence metastatic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>